Form 6-K ALTERITY THERAPEUTICS For: Nov 24

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 24, 2025

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1

Final Director’s Interest Notice - Meltzer

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

 

Date: November 24, 2025

 

ATTACHMENTS / EXHIBITS

FINAL DIRECTOR'S INTEREST NOTICE - MELTZER

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Analog Devices to Participate in the J.P. Morgan U.S. All Stars Conference
• SONEX HEALTH ANNOUNCES PUBLICATION OF LARGEST OFFICE-BASED ULTRASOUND-GUIDED CARPAL TUNNEL RELEASE STUDY WITH TWO-YEAR FOLLOW-UP
• Citadel Credit Union Closes Record $50 Million Commercial Real Estate Loan for 2000 Market Street